SEC Looks Into Dendreon Following FDA Disclosure
The inquiry comes on the heels of the U.S. Food and Drug Administration seeking more information from the company on the drug, a move that prompted a handful of shareholder lawsuits.
In a filing with the SEC Tuesday, Dendreon said that the New York Regional Office of the SEC notified the company on Monday that it was...
Already a subscriber? Click here to login